A high enthaply [i.e., enthalpy] test facility powered by a gaseous core reactor.

This thesis document was issued under the authority of another institution, not NPS. At the time it was written, a copy was added to the NPS Library collection for reasons not now known. It has been included in the digital archive for its historical value to NPS. Not believed to be a CIVINS (Civilian Institutions) title.The feasibility of utilizing a gaseous core nuclear reactor to provide high enthalpy, high pressure gas flow for simulating atmospheric re-entry conditions was inves­tigated. The test facility uses a mixture of nitrogen and uranium in a closed cycle with no attempt to contain the uranium fuel within the core. The primary purpose of the facility is to provide high enthalpy, high shear flows for testing re-entry materials and shapes. Investigated in this study were the effects of the nitrogen-uranium mixture on reactor criticality, nuclear contamination of the test model, protection of the reactor core and nozzle structure from imposed heat loads and operating limitations of the test facility."Acknowledgement is made to the Department of the Navy, and to the United States Postgraduate School, Monterey, California, who made this work possible."http://www.archive.org/details/highenthaplyieen00flynLieutenant, United States Nav

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Stardust Interstellar Preliminary Examination I: Identification of tracks in aerogel

Here, we report the identification of 69 tracks in approximately 250 cm2 of aerogel collectors of the Stardust Interstellar Dust Collector. We identified these tracks through Stardust@home, a distributed internet-based virtual microscope and search engine, in which > 30,000 amateur scientists collectively performed >9 × 107 searches on approximately 106 fields of view. Using calibration images, we measured individual detection efficiency, and found that the individual detection efficiency for tracks > 2.5 ?m in diameter was >0.6, and was >0.75 for tracks >3 ?m in diameter. Because most fields of view were searched >30 times, these results could be combined to yield a theoretical detection efficiency near unity. The initial expectation was that interstellar dust would be captured at very high speed. The actual tracks discovered in the Stardust collector, however, were due to low-speed impacts, and were morphologically strongly distinct from the calibration images. As a result, the detection efficiency of these tracks was lower than detection efficiency of calibrations presented in training, testing, and ongoing calibration. Nevertheless, as calibration images based on low-speed impacts were added later in the project, detection efficiencies for low-speed tracks rose dramatically. We conclude that a massively distributed, calibrated search, with amateur collaborators, is an effective approach to the challenging problem of identification of tracks of hypervelocity projectiles captured in aerogel